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1. INTRODUCTION {#lio2346-sec-0005}
===============

Laryngeal cancer is among the most common malignant tumors arising in the head and neck region. Although the overall incidence of squamous cell carcinoma of the larynx (SCC‐L) has decreased over time, the associated survival rates have also decreased in past decades.[1](#lio2346-bib-0001){ref-type="ref"} This change may be due to a shift from radical surgery to treatments such as radiotherapy (RT), chemoradiotherapy (CRT), and biotherapy, which aim to preserve the larynx and its functions.[2](#lio2346-bib-0002){ref-type="ref"}, [3](#lio2346-bib-0003){ref-type="ref"}, [4](#lio2346-bib-0004){ref-type="ref"} Although total laryngectomy followed by radiotherapy is usually recommended for the treatment of locally advanced laryngeal cancer, this procedure often causes difficulties with breathing, speaking, and smelling, which reduce the quality of life. For these reasons, many institutions opt for intensive treatments, such as CRT, to improve organ and functional preservation, despite the lower survival rates of patients who receive with nonsurgical treatments.[5](#lio2346-bib-0005){ref-type="ref"} The adverse effects of chemoradiation therapy, including laryngeal edema, mucosal fibrosis, and decreased laryngeal sensation, can lead to reduced respiratory and deglutitory functions. Generally, patients with T4 laryngeal cancer are treated via total laryngectomy according to the National Comprehensive Cancer Network (NCCN) guidelines.[6](#lio2346-bib-0006){ref-type="ref"} However, the management of advanced T2 or T3 laryngeal cancer has not been elucidated.

The selective radiotherapy and concomitant intra‐arterial cisplatin (RADPLAT) regimen was first reported by Robbins et al in 1992 and has since been used to improve organ and functional preservation.[7](#lio2346-bib-0007){ref-type="ref"} In Japan, reports have demonstrated favorable survival and organ preservation rates among patients with head and neck cancer who were treated with RADPLAT at several institutions.[8](#lio2346-bib-0008){ref-type="ref"}, [9](#lio2346-bib-0009){ref-type="ref"}, [10](#lio2346-bib-0010){ref-type="ref"}, [11](#lio2346-bib-0011){ref-type="ref"} A Dutch randomized phase 3 trial that compared RADPLAT with intravenous (IV) cisplatin‐based CRT did not identify any additional benefits of RADPLAT in terms of locoregional control (LRC) and survival.[12](#lio2346-bib-0012){ref-type="ref"} However, that trial did not include patients with laryngeal cancer.

Although few studies have evaluated the use of RADPLAT in patients with SCC‐L,[13](#lio2346-bib-0013){ref-type="ref"}, [14](#lio2346-bib-0014){ref-type="ref"} very little is known about the long‐term effects of this regimen on survival or the structural and functional preservation of the larynx. Accordingly, this retrospective study aimed to investigate survival outcomes, organ and functional preservation of the larynx, and toxicities in patients with advanced T2 or T3 SCC‐L who underwent RADPLAT at a single institution.

2. MATERIALS AND METHODS {#lio2346-sec-0006}
========================

2.1. *Patients* {#lio2346-sec-0007}
---------------

Untreated patients with histologically confirmed, locally advanced‐stage (advanced T2 or T3) SCC‐L were eligible for the study. Advanced T2 was defined as an impaired vocal fold or transglottic tumor spanning from the supraglottic to the subglottic site. Patients with level IV metastatic neck lymph nodes, distant metastases, bilaterally fixed vocal folds, a history of tracheostomy before treatment or cerebral infarction, and an Eastern Cooperative Oncology Group (ECOG) performance status \>2 were excluded from the study. TNM staging was determined according to the 7th Edition of the Union for International Cancer Control (UICC) staging system and was based on enhanced computed tomography (CT), magnetic resonance imaging (MRI), ultrasound examination, and positron emission tomography findings. All patients were assessed by a multidisciplinary team that included radiation oncologists, diagnostic radiologists, and head and neck surgeons.

The present study (Reference number: 18191) was conducted in accordance with the provisions of the Declaration of Helsinki and was approved by the Institutional Review Board of Kurume University Hospital. Informed consent was obtained from each patient.

2.2. *Treatments* {#lio2346-sec-0008}
-----------------

### 2.2.1. *Selective intra‐arterial cisplatin infusion* {#lio2346-sec-0009}

An intra‐arterial cisplatin infusion was administered by the diagnostic radiologist and radiation oncologist using the Seldinger technique, which involves a transcutaneous femoral insert. A microcatheter was inserted intra‐arterially and advanced selectively to the arteries that supplied nutrients to the tumors, including the superior thyroid artery and/or lingual artery. These nutrient‐supplying arteries were identified using cone‐beam CT and imaged using angiography (3D‐CTA). Before the infusion of cisplatin, a 5‐HTT3 receptor antagonist was administered intravenously to prevent nausea and vomiting. Cisplatin (75 mg body^−1^ wk^−1^) was administered intra‐arterially at a flow rate of 0.1 mg s^−1^. Simultaneously, sodium thiosulfate (20‐25 g) was administered intravenously to neutralize the acidity of cisplatin and reduce the incidence of systemic toxicities such as renal dysfunction or vessel damage. The catheters were removed after drug administration, and saline was administered for 24 hours to protect renal function. Cisplatin was administered four times (total 300 mg), although an additional one or two cycles (75‐150 mg) were given in cases with a suspected residual tumor.

2.3. *Radiotherapy* {#lio2346-sec-0010}
-------------------

External radiotherapy was administered to all patients five times per week (1.8 Gy fraction^−1^ d^−1^) using a three‐dimensional (3D) method and 4‐MV X‐ray beam linear accelerator. In the primary region, the gross tumor volume (GTV) was evaluated using CT and/or MRI, and the clinical target volume (CTV) was defined as the GTV plus a safety margin of 5 mm. The planning target volume was calculated as the CTV plus 5 to 10 mm. The neck irradiation fields in patients with glottic or supraglottic cancer with metastatic neck lymph nodes or T3 cancers included bilateral neck levels II, III, IVa, IVb + Vc; in patients with subglottic cancer or tracheal invasion, the fields included bilateral neck levels II, III, IVa, IVb + Vc, and VIb. In patients with T2 cancer without lymph node metastasis, the neck irradiation fields for supraglottic cancer included bilateral neck levels II, III, and IVa, while those for subglottic cancer included bilateral neck levels II, III, IVa, and VIb. Prophylactic neck irradiation was not administered to patients with T2 glottic cancer without metastatic neck lymph nodes.

2.4. *Statistical analysis* {#lio2346-sec-0011}
---------------------------

LRC, disease‐specific survival (DSS), and overall survival (OS) were calculated from the date of diagnosis using the Kaplan‐Meier method. Total laryngectomy, tracheostomy, and/or feeding tube placement/retention after 2 years of treatment were defined as events associated with laryngeal preservation (LP) and function.[15](#lio2346-bib-0015){ref-type="ref"} Freedom from laryngectomy (FFL) was defined according to the date of salvage laryngectomy for an event, while laryngectomy‐free survival (LFS) was defined according to the date of salvage laryngectomy and/or any death related to an events. The functional and mortality endpoints were evaluated using the laryngo‐esophageal dysfunction‐free survival (LEDFS), which included death, local recurrence, salvage total laryngectomy, tracheotomy, and/or feeding tube placement/retention recorded after 2 years of treatment. The survival rates were compared using a log‐rank test. Clinical variables associated with a *P* value \<.2 in the univariate analysis were subjected to a multivariate analysis using the Cox proportional hazard model. Probabilities \<.05 were considered statistically significant. All statistical analyses were conducted using JMP Pro 13 statistical software (SAS Institute, Cary, North Carolina).

3. RESULTS {#lio2346-sec-0012}
==========

3.1. *Patient characteristics* {#lio2346-sec-0013}
------------------------------

Between July 2006 and October 2016, 342 patients with laryngeal SCC were referred to the Kurume University Hospital. Of the 55 patients with advanced T2 or T3 deemed eligible for RADPLAT, six were excluded because of (a) catheter obstruction (n = 4), (b) severe cough due to stimulation of the inserted catheter (n = 1), and (c) aggressive growth of a double cancer (n = 1). Forty‐nine patients were eligible for the final evaluation, of whom 18 (37%) had an impaired or fixed vocal fold. The median age of the patients was 66 years (range: 37‐81), and the median follow‐up period was 64 months (range: 25.4‐145.2 months). The clinical features of the patients are shown in Table [1](#lio2346-tbl-0001){ref-type="table"}.

###### 

Patient characteristics (n = 49)

  Variables                   No. of patients (%)
  --------------------------- ---------------------
  Age                         
  Median                      66
  Range                       37‐81
  Sex                         
  Male                        46 (94)
  Female                      3 (6)
  Subsite                     
  Supraglottis                19 (39)
  Glottis                     27 (55)
  Subglottis                  3 (6)
  T classification            
  Advanced T2                 10 (20)
  T3                          39 (80)
  N classification            
  N0                          41 (84)
  N1                          1 (2)
  N2b                         4 (8)
  N2c                         3 (6)
  Clinical stage              
  II                          8 (16)
  III                         34 (70)
  IVA                         7 (14)
  Total cisplatin dose (mg)   
  Median                      300
  Range                       150‐450
  Total irradiation (Gy)      
  Median                      66
  Range                       60‐71
  Vocal fold movement         
  Impaired                    5 (10)
  Fixed                       13 (27)
  No                          31 (63)
  Follow‐up (mo.)             
  Median                      64
  Range                       25.4‐145.2

3.2. *Treatment outcomes* {#lio2346-sec-0014}
-------------------------

The total cisplatin dose range administered in this study was 150 to 450 mg, and the total irradiation dosage range was 60 to 71 Gy. At a total administered cisplatin dose of 150 mg and irradiation dose of 18 to 27 Gy, two of four patients had an early complete response (CR) to treatment at the local site as determined endoscopically, one had grade 3 dysphagia, and the fourth patient had a severe cough stimulated by inserting the catheter into the tumor feeding artery. In these patients, further cisplatin administration was stopped and radiotherapy alone was administered, although one patient also temporarily stopped receiving radiotherapy. At a total administered cisplatin dose of 225 mg and irradiation dose of 36 to 45 Gy, two of three patients achieved an early CR, and the third developed progressive disease. Further cisplatin administration was stopped in the first two patients, who were given sequential radiotherapy, while the third patient underwent total laryngectomy followed by postoperative irradiation at a dose of 36 Gy. Twenty‐eight patients achieved a clinical CR at a total administered cisplatin dose of 300 mg, although 14 had locally residual tumors. These latter patients received an additional cisplatin infusion (additional dose: 75‐150 mg, total dose: 375‐450 mg). The treatment regimens are summarized in Figure [1](#lio2346-fig-0001){ref-type="fig"}. The median cisplatin and irradiation doses were 300 mg (range: 150‐450 mg) and 66 Gy (range: 60‐71 Gy), respectively. Among all patients, eight presented with metastatic neck lymph nodes before treatment, and one underwent neck dissection for persistent metastatic lymph nodes after treatment. Local recurrences were observed in four patients, of whom three and one underwent total and partial laryngectomies, respectively. Deaths due to nonlaryngeal cancers were recorded for seven patients (ureteral cancer, n = 1; lung cancer, n = 2; colon cancer, n = 2; oral cancer, n = 1; esophageal cancer, n = 1), while deaths due to locoregional recurrences and distant metastases occurred in two and three patients, respectively.

![Schema of eligibility and response data to selective radiotherapy and concomitant intra‐arterial cisplatin (RADPLAT). CDDP, cisplatin; CR, complete response; PD, progressive disease](LIO2-5-55-g001){#lio2346-fig-0001}

3.3. *LRC and survival* {#lio2346-sec-0015}
-----------------------

Kaplan‐Meier analyses of the LRC, DSS, and OS rates for all patients and subsets according to T stage and clinical stage are shown in Figures [2A](#lio2346-fig-0002){ref-type="fig"} and 3, respectively. The 5‐year LRC, DSS, and OS rates for all patients were 83.3%, 88.1%, and 82.6%, respectively. The 5‐year LRC rates for patients with advanced T2 or T3 disease were 90% and 81.6%, respectively. The 5‐year DSS and OS rates for patients with advanced T2 disease were both 87.5%, while the rates for patients with T3 disease were 88.6% and 81.5%, respectively. The 5‐year LRC rates for patients with stage II, III, or IVA disease were 100%, 81.7%, and 71.4%, respectively. The 5‐year DSS rates for patients with stage II, III, or IVA disease were 100%, 93.3%, and 53.6% respectively, while the corresponding 5‐year OS rates were 100%, 84.8%, and 53.6%, respectively (Figure [3](#lio2346-fig-0003){ref-type="fig"}).

![Clinical outcomes after RADPLAT. Kaplan‐Meier curves of LRC, DSS, OS, FFL, LFS, and LEDFS in patients with all SCC‐L. DSS, disease‐specific survival; FFL, freedom from laryngectomy; LEDFS, laryngo‐esophageal dysfunction‐free survival; LFS, laryngectomy‐free survival; LRC, locoregional control; OS, overall survival; SCC‐L, squamous cell carcinoma of the larynx](LIO2-5-55-g002){#lio2346-fig-0002}

![Kaplan‐Meier curves of LRC, DSS, OS in patients with SCC‐L according to, A‐C, T stage and, D‐F, clinical stage. DSS, disease‐specific survival; LRC, locoregional control; OS, overall survival; SCC‐L, squamous cell carcinoma of the larynx](LIO2-5-55-g003){#lio2346-fig-0003}

3.4. *Organ and functional preservation* {#lio2346-sec-0016}
----------------------------------------

Kaplan‐Meier analyses of the FFL, LFS, and LEDFS rates for all patients and subsets according to T stage and clinical stage are shown in Figures [2B](#lio2346-fig-0002){ref-type="fig"} and 4, respectively. The 5‐year FFL, LFS, and LEDFS rates for all patients were 89.6%, 79.4%, and 77.1%, respectively. For patients with advanced T2 and T3 disease, the 5‐year FFL rates were 90% and 89.7%, respectively, the LFS rates were 90% and 76.8%, respectively, and the LEDFS rates were 90% and 73.8%, respectively. The 5‐year FFL rates for patients with stage II, III, or IVA disease were 100%, 91.2%, and 71.4%, respectively, while the corresponding LFS and LEDFS rates were 100%, 79.4%, and 57.1%, respectively, and 100%, 76.1%, and 57.1%, respectively (Figure [4](#lio2346-fig-0004){ref-type="fig"}).

![Kaplan‐Meier curves of FFL, LFS, and LEDFS in patients with SCC‐L according to, A‐C, T stage and, D‐F, clinical stage. FFL, freedom from laryngectomy; LEDFS, laryngo‐esophageal dysfunction‐free survival; LFS, laryngectomy‐free survival; SCC‐L, squamous cell carcinoma of the larynx](LIO2-5-55-g004){#lio2346-fig-0004}

3.5. *Prognostic factors* {#lio2346-sec-0017}
-------------------------

The results of the univariate analyses of LRC, DSS, and OS are shown in Table [2](#lio2346-tbl-0002){ref-type="table"}. No significant differences were observed in terms of the LRC. In contrast, statistically significant associations were observed between the DSS and the N classification (*P* = .021), clinical stage (*P* = .017), and total cisplatin dosage (*P* = .010). The clinical stage and total cisplatin dosage were not included in the multivariate analysis because they also exhibited significant correlations with the N classification (Table [S1](#lio2346-supitem-0001){ref-type="supplementary-material"}). The multivariate analyses identified the N classification as an independent and significant factor affecting DSS (hazard ratio \[HR\] = 6.64; 95% confidence interval \[CI\] = 1.07‐51.69, *P* = .042). The univariate analysis also indicated significant associations of the OS with the N classification (*P* = .020) and total cisplatin dosage (*P* = .037), while the multivariate analysis identified positive nodal disease as an independent and significant risk factor for OS (HR = 4.88; 95%CI = 1.42‐15.49, *P* = .014).

###### 

Univariate and multivariate analyses of clinical factors associated with locoregional control, disease‐specific survival, and overall survival

  Factor                         LRC   DSS                 OS                                                                                                        
  ------------------------------ ----- ------------------- ------------------- ------------------- --------------------------------------------- ------------------- -------------------
  Age (y)                                                                                                                                                            
  \<66                           24    .487                                    .114                .283                                          .420                
  ≥66                            25    0.60 (0.12‐2.47)                        4.78 (0.70‐93.60)   0.33 (0.02‐2.33)                              1.60 (0.51‐5.41)    
  Subsite                                                                                                                                                            
  Supraglottis                   19    .151                .243                .356                                                              .276                
  Sub or glottis                 30    2.79 (0.69‐13.62)   2.4 (0.55‐12.64)    2.30 (0.38‐17.44)                                                 1.88 (0.60‐6.39)    
  T classification                                                                                                                                                   
  T3                             39    .496                                    .805                                                              .096                .062
  Advanced T2                    10    1.95 (0.35‐36.57)                       1.31 (0.19‐25.60)                                                 4.26 (0.80‐78.67)   4.94 (0.93‐91.24)
  N classification                                                                                                                                                   
  N+                             8     .507                                    .021\*              .042[\*](#lio2346-note-0003){ref-type="fn"}   .020\*              .014\*
  N−                             41    1.77 (0.26‐7.68)                        8.66 (1.43‐65.97)   6.64 (1.07‐51.69)                             4.36 (1.28‐13.75)   4.88 (1.42‐15.49)
  Clinical stage                                                                                                                                                     
  IVA                            7     .408                                    .017\*                                                            .076                
  II‐III                         42    2.06 (0.30‐8.92)                        9.21 (1.52‐70.0)                                                  3.26 (0.87‐10.4)    
  Total CDDP dose                                                                                                                                                    
  \<375 mg                       35    .553                                    .010\*                                                            .037\*              
  ≥375 mg                        14    0.64 (0.16‐3.13)                        0.08 (0.004‐0.56)                                                 0.28 (0.09‐0.93)    
  Irradiation dose                                                                                                                                                   
  \<66 Gy                        24    .086                .105                .114                .293                                          .702                
  ≥66 Gy                         25    3.65 (0.84‐24.92)   3.48 (0.78‐24.21)   4.78 (0.71‐93.58)   2.99 (0.42‐59.67)                             0.80 (0.25‐2.59)    
  Vocal fold impaired or fixed                                                                                                                                       
  Yes                            18    .104                .394                .446                                                              .512                
  No                             31    0.23 (0.02‐1.30)    0.41 (0.02‐2.38)    0.45 (0.02‐3.06)                                                  0.65 (0.14‐2.20)    

Abbreviations: CDDP, cisplatin; CI, confidence interval; DSS, disease‐specific survival; HR, hazard ratio; LRC, locoregional control; OS, overall survival.

Cox proportional hazards model.

*P* \< .05.

3.6. *Toxicities* {#lio2346-sec-0018}
-----------------

Grade 3 and 4 hematologic and nonhematologic toxicities were observed in nine (18%) and three (6%) patients, respectively (Table [3](#lio2346-tbl-0003){ref-type="table"}). The following grade \>3 toxicity events were observed: leukopenia in six (12%) patients, neutropenia in seven (8%), anemia in two (4%), thrombocytopenia in two (4%), dysphagia in one (2%), and pharyngeal mucositis in two (4%) patients. Although one patient temporarily stopped receiving sequential irradiation because of grade 3 dysphagia, the patient eventually completed the planned irradiation dosage (total dose: 61 Gy). Late toxicities were observed in two patients. One patient developed chondronecrosis of the cricoid cartilage and underwent debridement of the affected lesion, which preserved the larynx. The other patient developed severe dysphasia 2 years after completing RADPLAT and underwent a laryngectomy.

###### 

Toxicity (n = 49)

  Acute toxicities          No. of patients (%)                      
  ------------------------- --------------------- --------- -------- -------
  Hematologic toxicity      19 (39)               18 (37)   8 (16)   1 (2)
  Leukopenia                9 (18)                17 (35)   6 (12)   0
  Neutropenia               10 (20)               9 (18)    6 (12)   1 (2)
  Anemia                    24 (49)               9 (18)    2 (4)    0
  Thrombocytopenia          14 (29)               1 (2)     2 (4)    0
  Renal failure             0                     0         0        0
  Nonhematologic toxicity   15 (31)               31 (63)   3 (6)    0
  Nausea/vomiting           4 (8)                 1 (2)     0        0
  Dysphagia                 15 (31)               15 (31)   2 (4)    0
  Mucositis                 18 (37)               28 (57)   2 (4)    0
  Fever                     2 (4)                 1 (2)     0        0
  Radiation dermatitis      27 (55)               21 (43)   0        0
  Lung infection            1 (2)                 0         0        0

4. DISCUSSION {#lio2346-sec-0019}
=============

Most previous studies reported that organ‐preserving therapies, including radiation therapy, chemoradiation therapy, and transoral laser microsurgery, are generally administered to patients with local early‐stage laryngeal cancers.[16](#lio2346-bib-0016){ref-type="ref"}, [17](#lio2346-bib-0017){ref-type="ref"}, [18](#lio2346-bib-0018){ref-type="ref"} In contrast, many patients with locally advanced tumors require radical surgery, including total or partial laryngectomy.[19](#lio2346-bib-0019){ref-type="ref"}, [20](#lio2346-bib-0020){ref-type="ref"}, [21](#lio2346-bib-0021){ref-type="ref"} In this study, the 5‐year LRC rates of patients with advanced T2 and T3 cancers were 90% and 81.6%, respectively, whereas the corresponding 5‐year DSS rates and OS rates were 87.5% and 88.6%, respectively, and 87.5% and 81.5%, respectively. Furthermore, for clinical stage II, III, and IVA disease, the 5‐year LRC rates were 100%, 81.7%, and 71.4%, respectively, the 5‐year DSS rates were 100%, 93.3%, and 53.6%, respectively, and the OS rates were 100%, 84.8%, and 53.6%, respectively. Table [4](#lio2346-tbl-0004){ref-type="table"} summarizes a literature review of the different therapeutic options. In several studies of surgical treatments, including total laryngectomy, the 5‐year OS rates ranged from 41% to 85.5%.[20](#lio2346-bib-0020){ref-type="ref"}, [22](#lio2346-bib-0022){ref-type="ref"}, [23](#lio2346-bib-0023){ref-type="ref"}, [24](#lio2346-bib-0024){ref-type="ref"}, [25](#lio2346-bib-0025){ref-type="ref"} Although it is difficult to compare these earlier results directly with our findings, the survival rates in our study tended to be favorable. Specifically, the nonsurgical treatments, including definitive RT and systemic CRT, yielded 5‐year local control (LC) or LRC rates of 62% to 65% and OS rates of 40 to 67% in patients with clinically advanced‐stage disease.[16](#lio2346-bib-0016){ref-type="ref"}, [26](#lio2346-bib-0026){ref-type="ref"}, [27](#lio2346-bib-0027){ref-type="ref"}, [28](#lio2346-bib-0028){ref-type="ref"}, [29](#lio2346-bib-0029){ref-type="ref"}, [30](#lio2346-bib-0030){ref-type="ref"} Al‐Mamgani et al reported a 5‐year LRC rate of 64% in patients with advanced T2 (T2b) disease treated with definitive RT.[16](#lio2346-bib-0016){ref-type="ref"} Additionally, Bhateja et al reported the 3‐year LRC rates of 73.2% and 91.5% in patients with (a) T2bN0 treated with RT or (b) T2b‐3N0‐2 treated with IV‐CRT, respectively, thereby demonstrating that CRT is a more favorable treatment for patients with T2b relative to RT alone.[30](#lio2346-bib-0030){ref-type="ref"} In a recent study of LP, Timme et al calculated a 2‐year LEDFS rate of 40% in patients with T3 disease treated with IV‐CRT.[24](#lio2346-bib-0024){ref-type="ref"} Fuller et al reported 5‐year LFS rates of 38% and 62% in patients with T3 disease treated with definitive RT or systemic CRT, respectively, and 5‐year LEDFS rates of 37% and 59% in patients with T3 disease treated with definitive RT or systemic CRT, respectively.[25](#lio2346-bib-0025){ref-type="ref"} Therefore, our findings appear to demonstrate more favorable outcomes of disease control, survival, and LP, compared to previous studies.

###### 

Summary of organ and functional preservation and survival of patients with laryngeal cancer

  Author                                                    No of patients                 Stage                      Treatment                       Laryngeal preservation       Local control and/or survival rates
  --------------------------------------------------------- ------------------------------ -------------------------- ------------------------------- ---------------------------- -------------------------------------
  **Surgical treatments**                                                                                                                                                          
  Chevalier et al[22](#lio2346-bib-0022){ref-type="ref"}    90                             T2                         CHEP                                                         5‐y LC: 95.4%
                                                            (impaired vocal cord motion)                                                              5‐y OS: 81.3%                
                                                                                                                                                      5‐y CSS: 96%                 
  22                                                        T3 (fixed vocal cord motion)   CHEP                                                       5‐y LC: 94.4%                
                                                                                                                                                      5‐y OS: 85.5%                
                                                                                                                                                      5‐y CSS: 94.1%               
  Canis et al[23](#lio2346-bib-0023){ref-type="ref"}        127                            pT2b                       Trans laser microsurgery                                     5‐y LC: 67.5%
                                                                                           ±Neck dissection                                           5‐y RFS: 57.3%               
                                                                                                                                                      5‐y DSS: 83.9%               
                                                                                                                                                      5‐y OS: 64.9%                
  122                                                       pT3                            Trans laser microsurgery                                   5‐y LC: 71.5%                
                                                                                           ±Neck dissection                                           5‐y RFS: 57.8%               
                                                                                                                                                      5‐y DSS: 84.1%               
                                                                                                                                                      5‐y OS: 58.6%                
  Timme et al[24](#lio2346-bib-0024){ref-type="ref"}        19                             T3                         Total or partial laryngectomy                                5‐y OS: 41%
  Fuller et al[25](#lio2346-bib-0025){ref-type="ref"}       125                            T3                         Total laryngectomy + RT                                      5‐y OS: 50%
                                                                                                                                                      5‐y DSS:61%                  
  Zhou et al[20](#lio2346-bib-0020){ref-type="ref"}         307                            T3                         Total or partial Laryngectomy   ‐                            5‐y DFS: 61.6%
                                                                                                                                                      (St III: 63.1%, IV: 33.3%)   
                                                                                                                                                      5‐y CSS: 71.5%               
                                                                                                                                                      (St III: 73.2%, IV: 40.2%)   
  **Nonsurgical treatments**                                                                                                                                                       
  Hinerman et al[26](#lio2346-bib-0026){ref-type="ref"}     82                             St III                     RT                                                           5‐y LRC: 62%
                                                            (all T3)                                                                                  5‐y CSS: 84%                 
                                                                                                                                                      5‐y OS: 52%                  
  Al‐Mamgani et al[27](#lio2346-bib-0027){ref-type="ref"}   170                            T3                         RT or IV‐CRT                    3‐y LFS: 76.8% (CRT)         5‐y LRC: 65%
                                                                                                                      3‐y LFS: 53.5% (RT)             5‐y DFS:60%                  
                                                                                                                                                      5‐y OS: 49%                  
  Al‐Mamgani et al[16](#lio2346-bib-0016){ref-type="ref"}   122                            T2b                        RT                                                           5‐y LC:64%
  Timme et al[24](#lio2346-bib-0024){ref-type="ref"}        25                             T3                         IV‐CRT                          2‐y LEDFS: 40%               5‐y OS: 40%
  Timmermans et al[28](#lio2346-bib-0028){ref-type="ref"}   84                             T3                         RT                                                           5‐y OS: 51%
  12                                                        T3                             IV‐CRT                                                     5‐y OS: 61%                  
  Fuller et al[25](#lio2346-bib-0025){ref-type="ref"}       121                            T3                         LP‐RT                           5‐y: LFS: 38%                5‐y OS: 46%
                                                                                                                      5‐y LEDFS: 37%                  5‐y DSS:64%                  
  166                                                       T3                             LP‐IV‐CRT                  5‐y: LFS: 62%                   5‐y OS: 67%                  
                                                                                                                      5‐y LEDFS: 59%                  5‐y DSS: 79%                 
  Gorphe et al[29](#lio2346-bib-0029){ref-type="ref"}       104                            T3                         IC→RT, IV‐CRT, or surgery       5‐y LP: 53.4%                5‐y DFS: 47.8%
                                                                                                                      5‐y LFS: 30%                    5‐y OS: 54.5%                
                                                                                                                      5‐y LEDFS: 28.2%                                             
  Bhateja et al[30](#lio2346-bib-0030){ref-type="ref"}      31                             T2bN0                      RT                                                           3‐y LC: 73.2%
  26                                                        T2b‐3 N0‐2                     IV‐CRT                                                     3‐y LC: 91.5%                
  Robbins et al[31](#lio2346-bib-0031){ref-type="ref"}      61                             St IV                      RADPLAT                                                      4‐y OS: 49.2%
  (larynx:11%)                                                                                                                                        4‐y LRC: 55.4%               
                                                                                                                                                      4‐y DFS: 34.7%               
  Yokoyama et al[32](#lio2346-bib-0032){ref-type="ref"}     23                             T3                         RADPLAT                         5‐y LP: 86%                  
  Yoshizaki et al[14](#lio2346-bib-0014){ref-type="ref"}    41                             St II‐IVA                  RADPLAT                                                      3‐y LC: 80.5%
                                                            (T2 and T3: 73%)                                                                          3‐y PFS: 53.7%               
                                                                                                                                                      3‐y OS: 82.9%                
  Furusaka et al[33](#lio2346-bib-0033){ref-type="ref"}     29                             T3                         ICT(IA + IV)                    5‐y LP: 92.5%                5‐y OS: 96.3%
                                                                                           →CRT (IA + IV)                                                                          
                                                                                           IA: CDDP+DOC                                                                            
                                                                                           IV: 5‐FU                                                                                
  Present study                                             10                             Advanced T2                RADPLAT                         5‐y FFL: 90%                 5‐y LRC: 90%
                                                                                                                      5‐y LFS: 90%                    5‐y DSS: 87.5%               
                                                                                                                      5‐y LEDFS: 90%                  5‐y OS: 87.5%                
  39                                                        T3                             RADPLAT                    5‐y FFL: 89.7%                  5‐y LRC: 81.6%               
                                                                                                                      5‐y LFS: 76.8%                  5‐y DSS: 88.6%               
                                                                                                                      5‐y LEDFS: 73.8%                5‐y OS: 81.5%                

Abbreviations: CDDP, cisplatin; CHEP, cricohyoidoepiglottopexy; CRT, chemoradiation therapy; CSS, cancer‐specific survival; DFS, disease‐free survival; DOC, docetaxel; DSS, disease‐specific survival; FFL, freedom from laryngectomy; ICT, induction chemotherapy; LC, local control; LEDFS, laryngo‐esophageal dysfunction‐free survival; LFS, laryngectomy‐free survival; LP, larynx preservation; LRC, locoregional control; OS, overall survival; PFS, progression‐free survival; RADPLAT, radiotherapy and concomitant intra‐arterial cisplatin; RFS, relapse‐free survival; RT, radiation therapy.

In a recent study on RADPLAT for head and neck cancers, Robbins et al demonstrated high rates of LRC, survival, and organ preservation in patients with locally advanced T4 tumors.[31](#lio2346-bib-0031){ref-type="ref"} Yokoyama et al reported a 5‐year LP rate of 86% in patients with T3 disease,[32](#lio2346-bib-0032){ref-type="ref"} while Yoshizaki et al reported 3‐year LC and OS rates of 80.5% and 82.9%, respectively, in patients with advanced SCC‐L.[14](#lio2346-bib-0014){ref-type="ref"} Furusaka et al further reported 5‐year LP and OS rates of 92.5% and 96.3%, respectively, in patients with T3 who were treated with an intra‐arterial (IA) cisplatin and docetaxel infusion combined with intravenous (IV) 5‐fluorouracil (5‐FU) infusion, followed by CRT via superselective IA chemotherapy with the same three drugs.[33](#lio2346-bib-0033){ref-type="ref"} Given those results, intra‐arterial CRT, including RADPLAT, were favorable and might be a suitable option for LP. However, this study had few patients with nodal disease or advanced clinical stage.

Regarding prognostic factors in laryngeal cancers, Zhou et al reported that high lymph node and stage statuses were predictors of disease‐free survival and cancer‐specific survival (CSS) in patients with T3 glottic cancer treated via surgery, including total or partial laryngectomy.[20](#lio2346-bib-0020){ref-type="ref"} Likewise, Nguyen‐Tan et al reported that a lower N status was a favorable prognostic factor of LRC and OS in patients with advanced T3‐T4 laryngeal carcinomas.[34](#lio2346-bib-0034){ref-type="ref"} Furthermore, Rosenthal et al and Timmermans et al reported an association of positive lymph node disease with overall mortality.[15](#lio2346-bib-0015){ref-type="ref"}, [28](#lio2346-bib-0028){ref-type="ref"} In our study, positive nodal disease was associated with a poor DSS and OS in a multivariate analysis. We therefore considered adjuvant therapy for patients with positive nodal‐stage cancer who had completed RADPLAT.

According to a randomized trial (RTOG 91‐11) conducted by the Radiation Therapy Oncology Group and the Head and Neck Intergroup, patients treated with cisplatin‐based IV‐CRT, experienced grade 3‐4 hematologic (47%), mucosal (43%), pharyngeal or esophageal (35%), and laryngeal (31%) toxicities. Grade 3‐4 nausea or vomiting (20%) and renal or genitourinary effects were also reported.[35](#lio2346-bib-0035){ref-type="ref"} A Dutch randomized trial reported grade \>2 hematological (52%), mucosal (50%), and renal (1%) toxicities in patients treated with intra‐arterial CRT, although grade \>2 renal toxicity was significantly less frequent in patients receiving intra‐arterial CRT, compared to intravenous CRT.[12](#lio2346-bib-0012){ref-type="ref"} In our study, we observed no renal toxicity, although grade 3‐4 leukopenia, neutropenia, anemia, and thrombocytopenia occurred in 12%, 14%, 4%, and 4% of the cases, respectively. The frequencies of these adverse reactions were much lower than those reported previously in patients who received IV‐CRT. Although the intra‐arterial approach via the Seldinger method has been reported to cause cerebrovascular accidents in some cases,[12](#lio2346-bib-0012){ref-type="ref"}, [31](#lio2346-bib-0031){ref-type="ref"} these did not occur in our study. Lin et al reported comparable survival outcomes in patients treated with surgery vs those who received complete CRT but not incomplete CRT.[36](#lio2346-bib-0036){ref-type="ref"} In other words, their study emphasized the importance of completing the full course of CRT.

In our study, only one patient temporarily discontinued treatment because of grade 3 toxicities. Robbins et al reported that 89 out of 213 patients with stage III or IV cancer who were treated with RADPLAT (150 mg m^−2^ wk^−1^ 4 and 68‐72 Gy) developed grade 3‐4 toxicities.[36](#lio2346-bib-0036){ref-type="ref"} The Radiation Therapy Oncology Group Trial 9615 reported grade 3‐5 hematologic and nonhematologic toxicity rates of 51% and 82%, respectively,[31](#lio2346-bib-0031){ref-type="ref"} whereas the corresponding rates in our study were 18% and 6%, respectively. The toxicity rates in our study were also much lower than those reported from the original RADPLAT studies by Robbins et al.[31](#lio2346-bib-0031){ref-type="ref"}, [37](#lio2346-bib-0037){ref-type="ref"} The lower toxicity rate in our study may be due to the lower dosage of intra‐arterial cisplatin (75 mg body^−1^ wk^−1^ × 2‐6 cycles; total median dosage, 300 mg body^−1^) than that used in previous reports.[31](#lio2346-bib-0031){ref-type="ref"}, [37](#lio2346-bib-0037){ref-type="ref"} Lambert et al reported that 23% of patients treated with IV‐CRT developed late toxicities, including percutaneous endoscopic gastrostomy (7%), persistent dysphagia (6%), pharyngoesophageal stenosis (2%), and permanent tracheostomy (8.5%).[38](#lio2346-bib-0038){ref-type="ref"} In our study, late toxicities such as chondronecrosis and severe dysphagia occurred in two patients (3.8%) within 5 years after RADPLAT, while no incident of late dysphagia occurred more than 5 years after RADPLAT. A long‐term follow‐up study of the RTOG 91‐11 trial reported a higher rate of death due to reasons other than laryngeal cancer in the CRT group, suggesting that a higher cisplatin dose affects OS by inducing a high incidence of adverse events in the CRT group.[39](#lio2346-bib-0039){ref-type="ref"} Although Furusaka et al reported higher rates of LP and survival in patients treated with three‐agent chemotherapy (IA cisplatin and docetaxel combined with IV 5‐fluorouracil), they also reported much higher grade 3‐4 leukopenia, neutropenia, and mucositis rates than those in observed in our study. The lower‐dose of cisplatin as a single agent and the lower frequencies of adverse events of our study may be due to the attempted long‐term preservation during treatment for advanced laryngeal cancer. Therefore, new strategies that would improve organ preservation and function while reducing morbidity are needed.

The present study had several limitations. First, it was a retrospective study with a small cohort. Second, all treatments were performed at a single institution. Third, eligible patients in this study were selected carefully, and the sample included few patients with nodal disease and an advanced clinical stage. Fourth, the frequency and total dose of cisplatin administration were not consistent. Further large‐cohort analyses are required to validate these findings.

In conclusion, our study demonstrates that RADPLAT therapy is safe and feasible in patients with laryngeal cancer while enabling organ and functional preservation. However, the treatment protocol should be standardized. Additionally, the feasibility of RADPLAT therapy in patients with nodal disease and advanced clinical stage should be validated further, as only a few such patients were included in our study.
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